{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"FE200486"},{"type":"CASRegistryName","name":"214766-78-6"},{"type":"USBrandName","name":"Firmagon"},{"type":"CodeName","name":"ASP3550"},{"type":"ChemicalStructureName","name":"N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide"}],"definition":{"html":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing  testosterone production by interstitial (Leydig) cells in the testes.","text":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing  testosterone production by interstitial (Leydig) cells in the testes."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/degarelix","text":"Degarelix"},"nciConceptId":"C48385","nciConceptName":"Degarelix","termId":441235,"name":"degarelix","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"degarelix"},{"aliases":[{"type":"CASRegistryName","name":"934246-14-7"},{"type":"ChemicalStructureName","name":"D-alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3- pyridinyl)-D-alanyl-L- seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]- L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L- lysyl-L-prolyl, acetate, hydrate"},{"type":"Synonym","name":"FE200486 acetate hydrate"}],"definition":{"html":"The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","text":"The acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes."},"drugInfoSummaryLink":null,"nciConceptId":"C80443","nciConceptName":"Degarelix Acetate","termId":813358,"name":"degarelix acetate","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"degarelix-acetate"}],"links":null}